Effect of Proparacaine in a Mouse Model of Allergic Rhinitis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives. Lidocaine, a local anaesthetic is a treatment option in uncontrolled asthma due to its immunomodulatory effects. In the present study, proparacaine (PPC), a derivative of lidocaine was examined for its therapeutic application in a mouse model of allergic rhinitis. Methods. The mice were grouped into 4 groups: control group, allergic rhinitis (AR) group, ciclesonide (CIC) group, and PPC group. Nasal symptom scores, eosinophil counts, goblet cell counts, and mast cells counts in the nasal mucosa were measured. Serum ovalbumin (OVA)-specific immunoglobulin (Ig) E, OVA-specific IgG1, OVA-specific IgG2a, interleukin (IL)-4, IL-5, and cortisol levels were measured. Results. Intranasal administration of PPC significantly decreased nasal symptoms, number of eosinophils, goblet cells, and mast cells in the lamina propria of the nasal mucosa. Serum OVA-specific IgE, OVA-specific IgG1, OVA-specific IgG2a was significantly higher in the AR compared with the control group. Serum level of IL-4 was significantly lower in the CIC group and PPC group in comparison with AR group. Serum IL-5 showed no significant difference among all groups. No significant difference in serum cortisol levels was observed among the 4 groups. Conclusion. PPC appears to have a therapeutic potential in treatment of allergic rhinitis in a mouse model by reducing eosinophil, goblet cell, and mast cell infiltration in the nasal mucosa.
Abstract
Objectives. Lidocaine, a local anaesthetic is a treatment option in uncontrolled asthma due to its immunomodulatory effects. In the present study, proparacaine (PPC), a derivative of lidocaine was examined for its therapeutic application in a mouse model of allergic rhinitis. Methods. The mice were grouped into 4 groups: control group, allergic rhinitis (AR) group, ciclesonide (CIC) group, and PPC group. Nasal symptom scores, eosinophil counts, goblet cell counts, and mast cells counts in the nasal mucosa were measured. Serum ovalbumin (OVA)-specific immunoglobulin (Ig) E, OVA-specific IgG1, OVA-specific IgG2a, interleukin (IL)-4, IL-5, and cortisol levels were measured. Results. Intranasal administration of PPC significantly decreased nasal symptoms, number of eosinophils, goblet cells, and mast cells in the lamina propria of the nasal mucosa. Serum OVA-specific IgE, OVA-specific IgG1, OVA-specific IgG2a was significantly higher in the AR compared with the control group. Serum level of IL-4 was significantly lower in the CIC group and PPC group in comparison with AR group. Serum IL-5 showed no significant difference among all groups. No significant difference in serum cortisol levels was observed among the 4 groups. Conclusion. PPC appears to have a therapeutic potential in treatment of allergic rhinitis in a mouse model by reducing eosinophil, goblet cell, and mast cell infiltration in the nasal mucosa.
참고문헌 (25)
- Bousquet J, "Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)", Allergy, 86, pp.8~160 (2008)
- Nicolaizik WH, "Endocrine and lung function in asthmatic children on inhaled corticosteroids", Am J Respir Crit Care Med, 150(3), pp.624~628 (1994)
- Phillip M, "Integrated plasma cortisol concentration in children with asthma receiving long-term inhaled corticosteroids", Pediatr Pulmonol, 12(2), pp.84~89 (1992)
- Toogood JH, "Effects of dose and dosing schedule of inhaled budesonide on bone turnover", J Allergy Clin Immunol, 88(4), pp.572~580 (1991)
- Okada S, "Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils", J Immunol, 160(8), pp.4010~4017 (1998)
- Serra MF, "Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma", Anesthesiology, 117(3), pp.580~591 (2012)
- Goldstein IM, "Influence of local anesthetics upon human polymorphonuclear leukocyte function in vitro: reduction of lysosomal enzyme release and superoxide anion production", J Exp Med, 146(2), pp.483~494 (1977)
- Sinclair R, "Inhibitory effects of amide local anaesthetics on stimulus-induced human leukocyte metabolic activation, LTB4 release and IL-1 secretion in vitro", Acta Anaesthesiol Scand, 37(2), pp.159~165 (1993)
- Tanaka A, "Inhibitory effect of lidocaine on T cells from patients with allergic asthma", J Allergy Clin Immunol, 109(3), pp.485~490 (2002)
- Suzuki T, "Influence of pH on the inhibitory effects of local anesthetics on histamine release induced from rat mast cells by concanavalin A and compound 48", 80, 1984, pp.98(3-4), 347~355
- Ohnishi T, "Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines", Clin Exp Immunol, 104(2), pp.325~331 (1996)
- Decco ML, "Nebulized lidocaine in the treatment of severe asthma in children:a pilot study", Ann Allergy Asthma Immunol, 82(1), pp.29~32 (1999)
- 이지은, "Antiallergic Function of KR62980, a Peroxisome Proliferator- Activated Receptor-γ Agonist, in a Mouse Allergic Rhinitis Model", Allergy, Asthma & Immunology Research, 7(3), pp.256~264 (2015), 대한천식알레르기학회
- Hunt LW, "Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study", J Allergy Clin Immunol, 113(5), pp.853~859 (2004)
- Hunt LW, "Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma", Mayo Clin Proc, 71(4), pp.361~368 (1996)
- Rosario NA, "Lidocaine nebulization for treatment of asthma", Ann Allergy Asthma Immunol, 85(3), pp.245~246 (2000)
- Talbot S, "Silencing nociceptor neurons reduces allergic airway inflammation", Neuron, 87(2), pp.341~354 (2015)
- Serra MF, "JM25-1, a lidocaine analog combining airway relaxant and antiinflammatory properties: implications for new bronchospasm therapy", Anesthesiology, 124(1), pp.109~120 (2016)
- Kessler TL, "Stimulation of goblet cell mucous secretion by activation of nerves in rat conjunctiva", Curr Eye Res, 14(11), pp.985~992 (1995)
- Rodrigues FV, "Effects of lidocaine with epinephrine or with buffer on wound healing in rat skin", Wound Repair Regen, 19(2), pp.223~228 (2011)
- Olsen PC, "Lidocaine-derivative JMF2-1 prevents ovalbumin-induced airway inflammation by regulating the function and survival of T cells", Clin Exp Allergy, 41(2), pp.250~259 (2011)
- Church MK, "The human mast cell", J Allergy Clin Immunol, 99(2), pp.155~160 (1997)
- 손혜림, "Effect of Retinoic Acid in a Mouse Model of Allergic Rhinitis", Allergy, Asthma & Immunology Research, 7(6), pp.590~598 (2015), 대한천식알레르기학회
- Liang MJ, "Immune responses to different patterns of exposure to ovalbumin in a mouse model of allergic rhinitis", Eur Arch Otorhinolaryngol, 273(11), pp.3783~3788 (2016)
- Newton R, "Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases", Pharmacol Ther, 125(2), pp.286~327 (2010)